Qiagen (NYSE:QGEN) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lessened its stake in Qiagen (NYSE:QGEN - Free Report) by 93.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,430 shares of the company's stock after selling 258,335 shares during the period. Exchange Traded Concepts LLC's holdings in Qiagen were worth $776,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its position in Qiagen by 3.9% in the third quarter. State Street Corp now owns 2,380,008 shares of the company's stock valued at $108,457,000 after purchasing an additional 90,181 shares during the period. Jennison Associates LLC raised its position in Qiagen by 5.0% in the third quarter. Jennison Associates LLC now owns 1,426,392 shares of the company's stock worth $65,001,000 after acquiring an additional 68,415 shares in the last quarter. XTX Topco Ltd raised its position in Qiagen by 129.3% in the third quarter. XTX Topco Ltd now owns 20,192 shares of the company's stock worth $920,000 after acquiring an additional 11,385 shares in the last quarter. Sanctuary Advisors LLC raised its position in Qiagen by 24.8% in the third quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company's stock worth $834,000 after acquiring an additional 3,878 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Qiagen by 36.0% during the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company's stock worth $73,096,000 after buying an additional 424,937 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on QGEN shares. Jefferies Financial Group restated a "buy" rating and set a $54.00 target price (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Hsbc Global Res upgraded Qiagen to a "hold" rating in a research report on Thursday, October 17th. HSBC downgraded Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a research report on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.50.

Qiagen Trading Up 1.8 %

Shares of NYSE QGEN traded up $0.77 on Thursday, reaching $44.54. 474,520 shares of the company traded hands, compared to its average volume of 1,121,989. Qiagen has a fifty-two week low of $40.15 and a fifty-two week high of $49.30. The company has a 50 day moving average of $44.81 and a 200 day moving average of $44.37. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $10.16 billion, a PE ratio of 114.32, a P/E/G ratio of 3.49 and a beta of 0.37.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.